Skip to main content
TLRY
NASDAQ Life Sciences

Tilray Q1 Revenue Jumps 23% to $257.1M, Reaffirms FY27 EBITDA Guidance

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.69
Mkt Cap
$549.011M
52W Low
$3.54
52W High
$23.2
52W Position info
4.2% above low
Off High info
84% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

TLRY is trading near its 52-week low of $3.54 (4.2% above the low).

Summary

Tilray reported record Q1 FY2027 revenue of $257.1 million, up 23% year-over-year, and reaffirmed its FY27 adjusted EBITDA guidance of $68 million to $75 million. The company posted a Q1 loss per share of 32 cents, which topped EPS expectations, with net loss of $40.0 million, adjusted net loss of $3.0 million, and adjusted EBITDA of $9.2 million. Gross profit reached a record for the first quarter, with margin around 30%, driven by double-digit year-over-year growth across international cannabis, beverage, and pharmaceutical distribution. The revenue increase reflects an 82% rise attributed to the BrewDog acquisition. This is the first look at the new fiscal year's top line and confirms the growth trajectory from the record FY2026 results reported in July. The reaffirmed guidance removes uncertainty around profitability targets. The stock trades near its 52-week low at $3.69, so a solid quarter with maintained guidance could support a re-rating. The company has been actively converting debt to equity, which adds share count but reduces leverage.

Updated with an SEC 8-K filing · What changed

Updates

  1. · Reuters — Analysts expected a loss of 20 cents per share on revenue of $267.46 million; shares fell 0.9% this quarter and 58.9% year-to-date.

    • Q1 adjusted loss of 32 cents per share was lower than prior year's breakeven EPS.
    • Wall Street's expected EPS range for the quarter was -32 cents to -7 cents.
    • Company reported a quarterly net loss of $43.14 million.
  2. · SEC 8-K — Tilray's 8-K attaches the press release with full financial statements and segment data; net loss was $40.0 million, adjusted net loss $3.0 million, and adjusted EBITDA $9.2 million.

At the time of this announcement, TLRY was trading at $3.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $549M. The 52-week trading range was $3.54 to $23.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

TLRY - Latest Insights

TLRY
Oct 08, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.70
Real-time Price: $3.43 info
Change: -$0.2707 (-7%) info
Market Cap: $506.893M info
TLRY
Sep 14, 2026, 5:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.17
Real-time Price: $3.43 info
Change: -$0.740 (-18%) info
Market Cap: $506.893M info
TLRY
Aug 10, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.42
Real-time Price: $3.43 info
Change: -$0.9946 (-22%) info
Market Cap: $506.893M info
TLRY
Jul 28, 2026, 5:03 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $4.09
Real-time Price: $3.43 info
Change: -$0.660 (-16%) info
Market Cap: $506.893M info
TLRY
Jul 28, 2026, 4:25 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.09
Real-time Price: $3.43 info
Change: -$0.655 (-16%) info
Market Cap: $506.893M info